These AMLs are characterized by the occurrence of one or more mutations of MDS-related genes, including SRFSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, and STAG2, defined by Lindsley et al. to be more than 95% specific for AMLs evolved from MDS or MDS/MPN [75]. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.